Does Blue Cross Blue Shield of Arizona Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Gets Complicated

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist manufactured by Eli Lilly. The FDA approved it in May 2022 as Mounjaro for type 2 diabetes management and in November 2023 as Zepbound specifically for chronic weight management. [1][2] The same molecule carries two separate National Drug Codes (NDCs), which matters enormously for insurance purposes because a plan that covers Mounjaro may not cover Zepbound, and vice versa.

Why the Same Drug Has Two Coverage Pathways

Insurers process drug claims by NDC and indication code. When a pharmacy submits a Mounjaro claim, the adjudication system checks whether the patient has an active type 2 diabetes diagnosis tied to the claim. A Zepbound claim routes to the plan's weight-management benefit, which may be carved out entirely, subject to different cost-sharing, or simply excluded on self-funded employer plans.

This split creates a situation where a patient with both type 2 diabetes and obesity could theoretically qualify under either pathway, but their physician's documentation must match whichever drug is prescribed.

The SURPASS and SURMOUNT Trial Data Driving Coverage Decisions

BCBSAZ medical policy reviewers cite published efficacy data when setting coverage criteria. Two trial programs are most referenced.

The SURPASS-2 trial (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg in adults with type 2 diabetes. At 40 weeks, HbA1c reductions were 2.01%, 2.24%, and 2.30% for the three tirzepatide doses versus 1.86% for semaglutide, with weight losses of 7.6 kg, 9.3 kg, and 11.2 kg respectively (P<0.001 for all comparisons). [3]

The SURMOUNT-1 trial (N=2,539) enrolled adults with BMI 30 or BMI 27 with at least one weight-related comorbidity but without diabetes. At 72 weeks, tirzepatide 15 mg produced a mean 20.9% body weight reduction versus 3.1% for placebo. [4] This dataset is what Eli Lilly submitted to the FDA for Zepbound approval and is frequently referenced in BCBSAZ's Zepbound prior authorization criteria language.

How BCBSAZ Plan Types Affect Tirzepatide Coverage

BCBSAZ administers several distinct plan categories, and the formulary for each can differ meaningfully. Checking your specific Summary of Benefits and Coverage (SBC) document is the only way to confirm your plan's rules.

Commercial Fully-Insured Plans

Fully-insured commercial plans sold to Arizona employers must comply with state insurance mandates. Arizona does not currently mandate coverage of GLP-1 agonists for obesity, so Zepbound coverage on these plans is discretionary. Many BCBSAZ commercial plans place Zepbound on Tier 4 or Tier 5 (specialty), with 20-33% coinsurance after deductible. Mounjaro for type 2 diabetes is more commonly covered, often at Tier 3 or Tier 4.

ACA Marketplace Plans (Individual and Small Group)

BCBSAZ Marketplace plans sold through HealthCare.gov follow ACA essential health benefit rules, but obesity drugs are not classified as an essential health benefit under the ACA framework. Coverage for Zepbound on these plans varies by metal tier and specific plan design. Bronze and Silver plans are less likely to include Zepbound than Gold or Platinum plans, where broader formularies are more common.

Medicare Advantage Plans

Medicare Part D has historically excluded most obesity drugs, but the Treat and Reduce Obesity Act has been debated in Congress for years. As of mid-2025, CMS finalized a rule allowing Medicare Part D plans to cover GLP-1 drugs approved for obesity beginning in 2026. [5] BCBSAZ Medicare Advantage members should verify with their 2026 Evidence of Coverage document once released. Mounjaro for type 2 diabetes is already covered under most Medicare Advantage Part D formularies with prior authorization.

Self-Funded (ASO) Employer Plans

Self-funded employer plans are governed by ERISA, not Arizona state insurance law. BCBSAZ acts as the administrator, but the employer sets the benefit design. Many large Arizona employers have explicitly excluded GLP-1 obesity drugs due to cost. If your plan excludes tirzepatide for obesity, an appeal based on medical necessity will almost certainly fail because the exclusion is contractual, not clinical. In that case, the physician's best path is to document type 2 diabetes as the primary indication and prescribe Mounjaro rather than Zepbound, if clinically appropriate.

Prior Authorization Criteria for Mounjaro (Diabetes Indication)

Prior authorization for Mounjaro through BCBSAZ generally requires all of the following, though exact criteria depend on plan year and formulary version.

Standard PA Requirements

• Confirmed diagnosis of type 2 diabetes (ICD-10: E11.x), not type 1 (E10.x) or unspecified (E14)
• HbA1c typically 7.5% or higher at the time of the request, though some plans use 8.0% as the threshold
• Documentation that the prescriber is managing the patient's diabetes (endocrinologist or primary care with diabetes management notes)
• Attestation that the patient is not using Mounjaro concurrently with another GLP-1 agonist or GIP/GLP-1 agonist

Step Therapy for Mounjaro

Most BCBSAZ commercial plans require documented use of metformin for at least 90 days with inadequate glycemic control before Mounjaro will be approved. Patients with documented metformin contraindications (e.g., eGFR <30 mL/min/1.73 m² per KDIGO guidelines) or intolerance (severe GI side effects documented in the chart) may qualify for a step therapy waiver. [6]

A prescriber note that simply states "patient cannot tolerate metformin" without a clinic visit documenting the symptoms is frequently insufficient. Chart notes should include the specific symptoms, the date they were documented, and that the prescriber discussed discontinuation of metformin as a result.

Prior Authorization Criteria for Zepbound (Obesity Indication)

Zepbound PA criteria are more stringent on most BCBSAZ plans because the obesity benefit is not mandated and insurers want to confirm clinical necessity.

BMI and Comorbidity Documentation

The plan typically requires one of the following:

• BMI 30 or greater (measured at a clinic visit within the past 12 months, not self-reported)
• BMI 27 or greater with at least one of the following comorbidities documented in the chart: hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease

The American Heart Association/American College of Cardiology/The Obesity Society 2013 guideline on the management of overweight and obesity in adults, which BCBSAZ references in several medical policies, defines clinically significant weight loss as 5-10% of initial body weight and supports pharmacotherapy for patients meeting these BMI criteria. [7]

Behavioral Intervention Requirement

Many BCBSAZ Zepbound PA submissions are denied because the patient lacks documentation of a structured weight-loss program. Most plans require evidence of at least 6 months of dietary counseling, a supervised exercise program, or a formal behavioral weight-loss program (e.g., an intensive behavioral therapy program billed under CPT 99401-99404 or G0447) within the prior 24 months.

Exclusions That Block Approval

Plans typically will not approve Zepbound if the patient has:

• A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2), per the FDA boxed warning [2]
• Active pancreatitis within the prior 12 months
• Current use of another GLP-1 or GIP/GLP-1 agonist

How to Submit a Prior Authorization Request That Succeeds

The majority of PA denials stem from incomplete documentation, not from patients who genuinely fail to meet criteria. A well-prepared submission dramatically improves first-pass approval rates.

What to Include in the Chart Notes Package

The prescriber's office should compile the following before submitting to BCBSAZ:

1. A complete problem list confirming the primary diagnosis (E11.x for T2D or the relevant obesity-related comorbidity ICD-10 code)
2. Most recent HbA1c lab result with the date drawn (for Mounjaro)
3. A clinic-visit note documenting measured height, weight, and calculated BMI (for Zepbound)
4. Documentation of prior therapy, including drug name, dates of use, and reason for discontinuation or inadequate response
5. Records from any behavioral or dietary counseling (for Zepbound)
6. The prescriber's clinical rationale, ideally citing the SURMOUNT-1 or SURPASS-2 efficacy data if relevant to the patient's specific situation

What Happens After Submission

BCBSAZ has up to 3 business days to respond to a non-urgent PA request under Arizona Department of Insurance rules. Urgent requests require a response within 24 hours. If the PA is approved, the authorization typically covers a 6-to-12-month supply before renewal is required.

If denied, BCBSAZ must provide a written denial notice specifying the clinical criteria the request failed to meet. This denial letter is the starting point for an appeal.

Appealing a Tirzepatide Denial from BCBSAZ

Denials are not final decisions. The appeals process has multiple stages, and published data suggest meaningful reversal rates for specialty medications when the appeal is well-documented.

Internal (First-Level) Appeal

The member or prescriber has 180 days from the denial notice to file an internal appeal with BCBSAZ. The appeal should include:

• A letter from the prescribing physician specifically addressing each criterion cited in the denial
• Any additional clinical records that were not included in the original PA submission
• Published clinical evidence supporting the drug's use for this patient's specific condition (peer-reviewed articles from PubMed are appropriate)

A study published in Health Affairs (2021) found that approximately 54% of prior authorization denials for specialty medications that were appealed internally were reversed. [8] That reversal rate drops significantly when appeals are filed without additional documentation versus the original submission.

External Review

If the internal appeal is denied, Arizona law entitles members to an independent external review through a state-certified Independent Review Organization (IRO). The Arizona Department of Insurance oversees this process. The IRO's decision is binding on BCBSAZ. External review is most likely to succeed when the denial was based on clinical criteria (medical necessity) rather than a blanket contractual exclusion.

The HealthRX clinical team developed a tiered documentation checklist for GLP-1 prior authorization submissions based on review of BCBSAZ denial letters across commercial and ACA Marketplace plans. In cases where prescribers submitted all checklist items at initial PA submission, first-pass approval rates were higher compared with submissions missing two or more items. This framework is reviewed quarterly as BCBSAZ updates its medical policies.

Cost Without Insurance: What Arizona Patients Pay Out of Pocket

If BCBSAZ denies coverage and the patient cannot afford the list price, several options may reduce the cost.

Eli Lilly Manufacturer Savings Programs

Eli Lilly offers a Mounjaro Savings Card for commercially insured patients who pay out of pocket. Eligible patients with commercial insurance may pay as little as $25 for a 1-month supply (up to a defined annual cap). The Zepbound Savings Card program offers similar savings for Zepbound. These savings cards do not work for Medicare or Medicaid beneficiaries, which is a federal anti-kickback constraint. [9]

Compounded Tirzepatide

During shortage periods, FDA-authorized 503A compounding pharmacies have been permitted to compound tirzepatide. The FDA removed tirzepatide from its drug shortage list in late 2024, which effectively ended the period when 503A and 503B compounders could legally produce tirzepatide copies. [10] Patients receiving compounded tirzepatide from pharmacies that have not halted production after the shortage designation was removed may be receiving product that does not meet current FDA standards for legally compounded drugs.

Self-Pay Cash Price

The retail cash price for tirzepatide in Arizona pharmacies is approximately $1,060-$1,070 per 4-week supply for the 5 mg starting dose, rising to approximately $1,070 for the 10 mg and 15 mg pens. GoodRx and similar discount programs offer modest reductions, typically bringing the price to $950-$1,000 per month, which is still out of reach for most patients without assistance.

Special Situations: When BCBSAZ Coverage Rules Differ

Patients with Both Type 2 Diabetes and Obesity

If a patient carries both diagnoses, the prescriber has a choice of NDC. In most cases, prescribing Mounjaro under the T2D indication is more likely to be approved than Zepbound under the obesity indication, particularly on self-funded employer plans. The prescriber should document the primary indication clearly in the chart and on the PA request.

Patients Transitioning from Semaglutide (Ozempic or Wegovy)

BCBSAZ plans that cover semaglutide may require a separate PA for tirzepatide, even if the patient has been stable on a GLP-1 agonist for years. Step therapy requirements may be considered satisfied if the chart documents prior semaglutide use with documented partial response. The prescriber's letter should explicitly state that the patient had an inadequate response (e.g., <5% weight loss at 12 weeks) or experienced a specific side effect that led to the transition.

Pediatric Patients

The FDA approved tirzepatide for chronic weight management in adolescents aged 12 and older in December 2024. [11] BCBSAZ coverage criteria for pediatric Zepbound use were still being updated as of mid-2025. Prescribers treating adolescent patients should call BCBSAZ Provider Services directly before submitting a PA to confirm current pediatric criteria, as standard adult BMI thresholds do not apply to patients under age 18.

What Your BCBSAZ Explanation of Benefits and Formulary Documents Tell You

Two documents available on the BCBSAZ member portal give the clearest picture of your specific coverage before you fill a prescription.

The Drug Formulary PDF

BCBSAZ publishes plan-specific formularies on its website. Search for "tirzepatide" or "Mounjaro" or "Zepbound" in the formulary PDF. The entry will show the tier number, any PA requirement (marked "PA"), and any quantity limits (marked "QL"). If the drug does not appear in the formulary at all, it is either not covered or is handled as a non-formulary exception, which requires a separate process.

The Summary of Benefits and Coverage

The SBC document, required under the ACA, lists the cost-sharing structure for specialty drugs and whether the plan covers "weight loss programs" as a benefit. A plan that excludes weight loss programs is unlikely to cover Zepbound regardless of PA approval.

Talking to Your BCBSAZ Provider Representative

Prescribers in Arizona can call the BCBSAZ Provider Services line (number listed on the back of the member's insurance card) to conduct a real-time coverage verification before submitting a PA. Asking specifically about the following items saves time:

• Whether tirzepatide (Mounjaro or Zepbound) appears on the plan's formulary under the member's specific group number
• The PA criteria document version currently in use
• Whether step therapy requirements have been met based on medication history on file
• The fax number and preferred submission format for the PA packet

Verbal coverage confirmations are not binding, but they help the prescriber decide whether to pursue the PA or redirect the patient to the Lilly savings card or alternative therapy.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Clinicians should offer pharmacotherapy to adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one obesity-related comorbidity, when lifestyle intervention alone has not achieved clinically meaningful weight reduction." [12] Presenting this guideline language in a PA letter or appeal reinforces the medical necessity argument and grounds the request in authoritative clinical consensus rather than marketing claims.

For Mounjaro specifically, the American Diabetes Association Standards of Care in Diabetes (2024) recommends GLP-1 receptor agonists and dual GIP/GLP-1 agonists with proven cardiovascular benefit as preferred agents in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, independent of HbA1c level. [13] If your patient carries a cardiovascular comorbidity, citing ADA Section 9 in the PA letter adds clinical weight that reviewers must address in any denial.